2.1. Subject Disposition and Baseline Characteristics
In the SAKURA phase 3 program, 2786 subjects received DAXI 40U, of whom 882 received two treatments and 568 received three treatments. Overall, 2823 subjects were exposed to RTP004, which included 2786 exposed through the active DAXI formulation and an additional 37 subjects who received placebo in SAKURA 1 and 2, did not roll over into the open-label SAKURA 3 study, and thus were exposed only to RTP004 and not DAXI. A total of 914 subjects had at least two exposures and 702 had three exposures to RTP004. The disposition of subjects in the SAKURA studies, including the number of evaluable subjects with baseline and at least one post-baseline antibody assessment (2737 for daxibotulinumtoxinA and 2772 for RTP004; ~98%), is shown in 